Histone Deacetylase Inhibitors Market is Projected to Grow Expeditiously: to Reach $1.71 Billion by 2029

 Offering reliable and timely data, this report is a key resource for anyone building or refining their histone deacetylase inhibitors industry roadmap.

How Much Is The Histone Deacetylase Inhibitors Market Worth?
The histone deacetylase inhibitors market size has grown strongly in recent years. It will grow from $1.2 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to regulatory support and fast-track approvals, the growing prevalence of cancer, increased funding for cancer research, the expansion of therapeutic applications, and increased expenditure on healthcare infrastructure.

The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growing investment in biotechnology, the growing elderly population, favorable regulatory approvals and faster drug approval processes, improved drug delivery systems, and the expansion of therapeutic applications. Major trends in the forecast period include the integration of wearable devices to monitor patient health, innovations in nanotechnology and drug delivery methods, advances in identifying and validating biomarkers, artificial intelligence (AI) and machine learning, and next-generation sequencing.

Get your free sample today:
Histone Deacetylase Inhibitors Market Trends & Outlook By 2034 Sample

What Are The Current Leading Growth Drivers For Histone Deacetylase Inhibitors Market?
The increasing incidence of cancer is expected to propel the growth of the histone deacetylase inhibitors market going forward. The rising incidence of cancer is primarily attributed to aging populations, increased exposure to risk factors such as tobacco, diet, and environmental pollutants, and improved diagnostic techniques leading to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, leading to the activation of tumor suppressor genes and suppression of oncogenes, thereby inducing cell cycle arrest and apoptosis in cancer cells. For instance, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases were predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing incidence of cancer is driving the growth of the histone deacetylase inhibitors market.

Which Segment Accounted For The Largest Histone Deacetylase Inhibitors Market Share?
The histone deacetylase inhibitors market covered in this report is segmented –

1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)

Emerging Trends And Strategic Opportunities In The Histone Deacetylase Inhibitors Market
Major companies operating in the histone deacetylase inhibitors market are focusing on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to expand treatment options and improve patient convenience and compliance. An oral histone deacetylase (HDAC) inhibitor is a drug taken by mouth that targets HDAC enzymes involved in gene regulation and is potentially used in treating various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, received Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat is a histone deacetylase (HDAC) inhibitor that mitigates the sequence of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD. By inhibiting HDAC overactivity, it reduces inflammation and fibrosis while promoting muscle fiber regeneration. The approval is based on the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients on Duvyzat showed a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.

Which Are The Top Companies To Hold The Market Share In Histone Deacetylase Inhibitors Market?
Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC

View the full histone deacetylase inhibitors market report here:
Histone Deacetylase Inhibitors Market Trends & Outlook By 2034

Which Region Is Projected To Account For The Largest Share Of The Histone Deacetylase Inhibitors Market?
North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: The Business Research Company | LinkedIn